The U.S. SEC has approved 21Shares’ spot XRP ETF for the U.S. market. The product will mirror the CME CF XRP-Dollar Reference Rate, giving holders access to the value of XRP. 21Shares has confirmed that its U.S. spot XRP ETF will begin trading on Monday. The U.S. Securities and Exchange Commission (SEC) approved the launch [...]]]>The U.S. SEC has approved 21Shares’ spot XRP ETF for the U.S. market. The product will mirror the CME CF XRP-Dollar Reference Rate, giving holders access to the value of XRP. 21Shares has confirmed that its U.S. spot XRP ETF will begin trading on Monday. The U.S. Securities and Exchange Commission (SEC) approved the launch [...]]]>

Spot XRP ETF Set for Monday Debut as 21Shares Finalizes TOXR Listing

  • The U.S. SEC has approved 21Shares’ spot XRP ETF for the U.S. market.
  • The product will mirror the CME CF XRP-Dollar Reference Rate, giving holders access to the value of XRP.

21Shares has confirmed that its U.S. spot XRP ETF will begin trading on Monday. The U.S. Securities and Exchange Commission (SEC) approved the launch through an 8-A filing that was filed on November 7.

As a result, it became automatically effective after the standard review period. The ETF will carry a 0.50% management fee and aims to raise $500,000 in initial capital under the ticker TOXR.

In terms of benchmark and structure, the ETF is specifically designed to track the spot price of XRP using the CME CF XRP–Dollar Reference Rate (XRPUSD_NY), calculated by a regulated benchmark provider. By doing so, investors can get direct exposure to XRP’s spot price without the need to purchase, store, or manage the cryptocurrency.

Also, both retail and institutional investors gain exposure to XRP through traditional brokerage accounts. This then makes entry into the market simpler, as XRP joins Bitcoin (BTC) and Ethereum (ETH).

With the launch of 21Shares’ spot XRP ETF, the firm now joins the ranks of major issuers in the U.S. cryptocurrency ETF space. This marks the fifth XRP-focused ETF to debut in the U.S. market in just a matter of days, following recent listings from providers such as Grayscale and Franklin Templeton.

Grayscale’s GXRP saw inflows of $67.36 million, while Franklin Templeton’s XRPZ attracted $62.59 million. Earlier, the market also saw the launch of spot ETFs for other cryptocurrencies, including Dogecoin (DOGE), Hedera (HBAR), and Litecoin (LTC).

XRP’s Market Activity

Data from SoSoValue shows that the daily total net inflow for the U.S. XRP spot ETF reached $22.68 million, contributing to a cumulative net inflow of $666.61 million. The fund’s total value traded stood at $21.38 million, while total net assets climbed to $687.81 million, reflecting solid investor demand.

Analysis of XRP derivatives indicates that trading volume has increased by 25.29%, reaching a total of $5.96 billion. The open interest, which tracks the total number of outstanding derivatives contracts, declined by 0.05% to $4.19 billion.

XRP is currently trading at $2.20, up 14% from the previous week. Its market capitalization settles at $131 billion, while its 24-hour trading volume of $3.01 billion has increased by 23% in the past day.

]]>
Market Opportunity
XRP Logo
XRP Price(XRP)
$2.0686
$2.0686$2.0686
-1.33%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26